No Increase in Blood Pressure Assessed With the 24-h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti-CGRP Monoclonal Antibodies: A Prospective Observational Study (SAFHYPER)

What Was Tested

Researchers studied CGRP (Calcitonin Gene-Related Peptide) in the context of low blood pressure and orthostatic hypotension and migraine in this observational study publication.

Herein, the researchers assess the early changes in blood pressure (BP) during anti-CGRP mAbs treatment in patients with migraine using 24-h Holter monitoring.

Who Took Part

According to the abstract, 20 patients were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The researchers conducted a prospective, real-world study including 20 patients with episodic migraine (EM) during the early treatment with anti-CGRP mAbs.

Participants underwent 24-h Holter BP monitoring before treatment and 4 weeks after the first injection.

How the Study Was Run

The primary outcome was the change in mean systolic BP (SBP).

Secondary outcomes included changes in diastolic BP (DBP), differential BP, diurnal/nocturnal values, heart rate (HR), and dipping patterns.

What Was Measured

Herein, the researchers assess the early changes in blood pressure (BP) during anti-CGRP mAbs treatment in patients with migraine using 24-h Holter monitoring.

Topics PubMed links to this paper include Migraine Disorders, Blood Pressure, Antibodies, Monoclonal, Calcitonin Gene-Related Peptide, Electrocardiography, Ambulatory and Blood Pressure Monitoring, Ambulatory.

The authors tagged it with the keywords CGRP, cardiovascular events, hypertension and safety.

What This Means in Plain Language

This is an observational study of CGRP (Calcitonin Gene-Related Peptide) in 20 patients in people with low blood pressure and orthostatic hypotension.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (European journal of neurology), a journal based in England.

More context: the CGRP (Calcitonin Gene-Related Peptide) compound page, Low blood pressure and orthostatic hypotension research, Migraine research.